US 12,220,501 B1
Injectable hydrogel for treatment of segmental bone defect
Chin-Chean Wong, Taipei (TW)
Assigned to TAIPEI MEDICAL UNIVERSITY, Taipei (TW)
Filed by TAIPEI MEDICAL UNIVERSITY, Taipei (TW)
Filed on Aug. 29, 2023, as Appl. No. 18/239,216.
Claims priority of application No. 112127852 (TW), filed on Jul. 26, 2023.
Int. Cl. A61L 27/52 (2006.01); A61L 27/26 (2006.01); A61L 27/36 (2006.01); A61L 27/48 (2006.01); A61L 27/54 (2006.01)
CPC A61L 27/52 (2013.01) [A61L 27/26 (2013.01); A61L 27/3616 (2013.01); A61L 27/365 (2013.01); A61L 27/48 (2013.01); A61L 27/54 (2013.01); A61L 2400/06 (2013.01); A61L 2430/02 (2013.01)] 10 Claims
OG exemplary drawing
 
1. An injectable hydrogel precursor composition consisting of:
about 10% by weight of gelatin, based on the total weight of the composition;
about 0.5-2% by weight of hyaluronic acid, based on the total weight of the composition;
about 0.5-1.0% by weight of genipin, based on the total weight of the composition; and
an aqueous medium having a pH ranging from 6-8;
wherein the injectable hydrogel precursor composition is in form of a clear solution through mixing and adapted to transition into a hydrogel at 37° C. with a gelation time ranging from 10 minutes to 40 minutes while remaining injectable at room temperature for at least 60 minutes, and the hydrogel has a compressive strength ranging from 300 kPa to 500 kPa.